🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
INCY
NASDAQ
🇺🇸 US
Incyte Corporation
Pharmaceuticals
17Score
DipBuster Score™
$125.65
$1.1 (-0.87%)
Live price · Source: Yahoo
52-Week Position
$81.09
87% of range
$132.60
Beta
0.77
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.77
52W High$132.60
52W Low$81.09
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Bearish
Near 52-Week High — Asymmetric Risk
At 87% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position87% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.77
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Incyte Corporation (INCY), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-08-25 | Basi Ramitpal K | SELL | 504 |
| 2026-08-12 | Cagnoni Pablo J | SELL | 10,803 |
| 2026-08-05 | Mayes Patrick A | SELL | 2,207 |
| 2026-08-05 | Mayes Patrick A | SELL | 2,207 |
| 2026-08-05 | Mayes Patrick A | BUY | 2,207 |
| 2026-08-05 | Cagnoni Pablo J | SELL | 10,640 |
| 2026-08-03 | Mayes Patrick A | SELL | 6,055 |
| 2026-08-03 | Mayes Patrick A | SELL | 6,055 |
| 2026-08-03 | Mayes Patrick A | BUY | 6,055 |
| 2026-07-31 | Mayes Patrick A | SELL | 326 |
Graham NCAV Analysis
Above net-net level
Current Assets$5.02B
Less: Total Liabilities−$1.79B
= Net Current Asset Value$3.23B
NCAV Per Share$16.2925
Current Price$128.00
Price / NCAV7.86×
Margin of Safety-685.6%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
Beta0.77
Dividend/yrNone
52W High$132.60
52W Low$81.09
52-Week Range
$81.09Now$132.60
87% through annual range
From 52W High−5.2%
From 52W Low+55%
📖 Plain English Summary
Incyte Corporation is at 87% of its 52-week range. Beta 0.77 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for INCY
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — INCY
Heuristic · balance sheet, insider filings, price data, academic research
Incyte Corporation — DipBuster Score 17/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Incyte Corporation free
Add INCY to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Hargreaves Lansdown
UK's #1 investment platform. ISA, SIPP, GIA. FCA regulated since 1981.
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
5/25
Momentum & Volume
7/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
3
/100 · NEUTRAL
dip depth
1/25
oversold rsi
0/25
mean reversion
2/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 17/100
📊
Run a full check in the AI analysis tab for a deeper look.
Company Profile
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and po…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
William J. Meury
Staff
2,844 employees
Website